Security
Immutep Ltd Ordinary Shares · PRRUF
PRRUFOTCCommon stockCurrentCIK 1506184Updated Nov 5, 2026
Name history
Prima BioMed Ltd · through Dec 1, 2017
PRRUF price & chart
Loading TradingView…
OTC:PRRUF on TradingView ↗About the company
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,826Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodAUD | — | — | — | 148,303Source |
| AdjustmentsForSharebasedPaymentsAUD | 1,163,543Source | 1,796,286Source | 2,001,572Source | 1,486,841Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | 3,165,899Source | -283,057Source | -296,038Source | — |
| GeneralAndAdministrativeExpenseAUD | 8,644,503Source | 8,852,615Source | 8,679,840Source | 7,210,123Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesAUD | 0Source | 0Source | 0Source | 34Source |
| InterestPaidClassifiedAsFinancingActivitiesAUD | 36,759Source | 30,328Source | 8,818Source | 9,712Source |
| InterestPaidClassifiedAsOperatingActivitiesAUD | 35,545Source | 30,009Source | 20,541Source | — |
| InterestReceivedClassifiedAsOperatingActivitiesAUD | 3,716,331Source | 3,695,594Source | 917,997Source | 224,656Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesAUD | 270,666Source | 226,494Source | 211,974Source | 222,536Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesAUD | 225,414Source | 903,154Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueAUD | 10,331,373Source | 7,838,625Source | 5,200,128Source | 6,758,073Source |
| Additional Financial Items | ||||
| AdministrativeExpenseAUD | 3,554,058Source | 4,229,578Source | 3,711,789Source | 3,321,923Source |
| BasicEarningsLossPerShareAUD/shares | -0.04Source | -0.04Source | -0.04Source | -0.04Source |
| CurrentTaxExpenseIncomeAUD | — | — | — | 34Source |
| DeferredTaxExpenseIncomeAUD | — | — | — | 0Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossAUD | 0Source | 0Source | 0Source | 0Source |
| DepreciationAndAmortisationExpenseAUD | 2,389,524Source | 2,261,858Source | 2,061,819Source | 2,063,462Source |
| DepreciationRightofuseAssetsAUD | 255,110Source | 248,764Source | 202,605Source | 224,406Source |
| DilutedEarningsLossPerShareAUD/shares | -0.04Source | -0.04Source | -0.04Source | -0.04Source |
| EmployeeBenefitsExpenseAUD | 10,772,257Source | 8,824,161Source | 6,527,725Source | 4,966,304Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesAUD | 1,163,543Source | 1,796,286Source | 2,001,572Source | 1,486,841Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedAUD | 5,580Source | 4,705Source | 5,782Source | 9,518Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedAUD | 3,216Source | 3,165Source | 6,539Source | 2,376Source |
| FinanceCostsAUD | 37,078Source | 30,594Source | 20,401Source | 92,430Source |
| GeneralAndAdministrativeExpenseAUD | 8,644,503Source | 8,852,615Source | 8,679,840Source | 7,210,123Source |
| IncomeTaxExpenseContinuingOperationsAUD | 0Source | 0Source | 0Source | 34Source |
| InterestExpenseOnLeaseLiabilitiesAUD | 36,283Source | 30,272Source | 8,678Source | 10,462Source |
| NetForeignExchangeLossAUD | 1,529,309Source | — | 0Source | 0Source |
| ProfitLossAttributableToOwnersOfParentAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,826Source |
| ProfitLossBeforeTaxAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,792Source |
| ResearchAndDevelopmentExpenseAUD | 49,778,916Source | 31,472,063Source | 28,793,385Source | 25,337,538Source |
| RevenueFromInterestAUD | 5,287,209Source | 3,882,757Source | 938,999Source | 224,520Source |
Filing attachments
d84185dex991.htm · 6-K · 2026-11-10
Exhibit 99.1 IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses Statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers, with greater pharmacodynamic effects at higher IMP761 exposure Well tolerated across all seven dose levels; pharmacokinetic (PK) profile supports a four-week dosing interval The multiple ascending dose…
Read attachment ↗d183841dex991.htm · 6-K · 2026-11-02
Exhibit 99.1 ASX / Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY27 Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and study start targeted for H2 CY27. IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune diseases, is now a co-priority alongside efti and will be the subject of a late breaking po…
Read attachment ↗d51422dex991.htm · 6-K · 2026-10-29
Exhibit 99.1 Immutep Receives A$2.16 million French R&D Tax Incentive SYDNEY, AUSTRALIA - 28 October, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program, for eligible R&D activities conducted…
Read attachment ↗d109552dex416.htm · 20-F · 2026-10-23
Exhibit 4.16 CONFIDENTIAL CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE AGREEMENT T HIS L ICENSE A GREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), by and between I MMUTEP S.A.S., a company having an address at Parc Les Algorithmes, B…
Read attachment ↗d36112dex991.htm · 6-K · 2026-10-14
Exhibit 99.1 Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement SYDNEY, AUSTRALIA - October 13, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated 12 October 2026 (US Eastern Time), confirming that the Company has regained com…
Read attachment ↗d79097dex991.htm · 6-K · 2026-09-22
Exhibit 99.1 Change to American Depositary Share Ratio SYDNEY, AUSTRALIA - September 21, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a change to the ratio of its American Depositary Shares (“ADSs”), which are quoted on the Nasdaq Global Market under the symbol IMMP. With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Easte…
Read attachment ↗